Iron chelation adherence to deferoxamine and deferasirox in thalassemia

American Journal of Hematology

Volumn 86, Issue 5, 2011, Pages 433-436

  Trachtenberg, Felicia ^a   Vichinsky, Elliott ^b   Haines, Dru ^b   Pakbaz, Zahra ^b   Mednick, Lauren ^c   Sobota, Amy ^c   Kwiatkowski, Janet ^d   Thompson, Alexis A ^e   Porter, John ^f   Coates, Thomas ^g   Giardina, Patricia J ^h   Olivieri, Nancy ⁱ   Yamashita, Robert ^j   Neufeld, Ellis J ^c  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j CALIFORNIA STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE;

ADULT; ALPHA THALASSEMIA; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; DEPRESSION; FEMALE; GASTROINTESTINAL PAIN; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; SMOKING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; BENZOIC ACIDS; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; GREAT BRITAIN; HUMANS; IRON CHELATING AGENTS; MALE; MEDICAL RECORDS; MEDICATION ADHERENCE; MIDDLE AGED; NORTH AMERICA; RETROSPECTIVE STUDIES; SELF REPORT; THALASSEMIA; TRIAZOLES; YOUNG ADULT;

EID: 79955151475     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21993     Document Type: Article

References (12)

1. Goldbeck L, Baving A, Kohne E. Psychosocial aspects of beta-thalassemia: Distress, coping and adherence. Klinische Padiatrie 2000; 212: 254-259.
2. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 2007; 47: 1919-1929.
3. Porter J, Wood J, Olivieri N, et al. Randomized, double-blind, placebo-controlled trial comparing the effect of deferoxamine with or without oral deferiprone on left ventricular function assessed by mri in adults with transfusion-dependent beta-thalassemia. (in press).
4. Evangeli M, Mughal K, Porter JB. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Hemoglobin 2010; 34: 305-321.
5. Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta haematologica 2002; 107: 150-157.
6. Thuret I, Hacini M, Pegourie-Bandelier B, et al. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. Hematology (Amsterdam, Netherlands) 2009; 14: 315-322.
7. Koch DA, Giardina PJ, Ryan M, et al. Behavioral contracting to improve adherence in patients with thalassemia. J Pediatrc Nurs 1993; 8: 106-111.
8. Garbowski M, Eleftheriou P, Pennell D, et al. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox. Blood 2008; 112:Abstract n116.
9. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3.
10. Snaith R, Zigmond A. The Hospital Anxiety and Depression Scale Manual. London, UK: nferNelson; 1994.
11. Ware JE, Kosinski M, Bjorner BB, et al. User's Manual for the SF-36v2 Health Survey, 2nd ed. Lincoln, RI: Quality Metric Incorporated; 2007.
12. Landgraf JM, Abetz L, Ware JE. Child Health Questionnaire (CHQ): A User's Manual, Third Printing. Lincoln, RI: Quality Metric Incorporated; 2006.